Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 3/20 | 0.88 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.88 |
| ▸ | AURKA | O14965 | 2/20 | 0.88 |
| ▸ | CHAT | P28329 | 2/20 | 0.88 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.88 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.88 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Coenzyme_A SCHEMBL2831401 | 0.95 | EP300 (0.88) | EP300NAA50AURKACHATKAT5 | |
| Coenzyme_A SCHEMBL2833078 | 0.95 | EP300 (0.88) | EP300NAA50AURKACHATKAT5 | |
| Coenzyme_A SCHEMBL2833005 | 0.95 | EP300 (0.88) | EP300NAA50AURKACHATKAT5 | |
| Coenzyme_A SCHEMBL88057 | 0.95 | EP300 (0.88) | EP300NAA50AURKACHATKAT5 | |
| Coenzyme_A SCHEMBL16974417 | 0.94 | EP300 (0.87) | EP300NAA50AURKACHATKAT5 | |
| Coenzyme_A SCHEMBL15969462 | 0.94 | EP300 (0.89) | EP300NAA50AURKACHATKAT5 | |
| SCHEMBL16216009 | 0.94 | EP300 (0.86) | EP300NAA50AURKACHATKAT5 | |
| SCHEMBL16216000 | 0.94 | EP300 (0.86) | EP300NAA50AURKACHATKAT5 | |
| Coenzyme_A SCHEMBL18675521 | 0.94 | EP300 (1.00) | EP300NAA50AURKACHATKAT5 | |
| Coenzyme_A SCHEMBL26752 | 0.94 | EP300 (1.00) | EP300NAA50AURKACHATKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10316064-B2 | Teicoplanin analogs and uses thereof | ACADEMIA SINICA (TW) | 2019-06-11 | — | — | US | disclosed |
| US-20170327542-A9 | TEICOPLANIN ANALOGS AND USES THEREOF | ACADEMIA SINICA (TW) | 2017-11-16 | — | — | US | disclosed |
| EP-3099703-A1 | TEICOPLANIN ANALOGS AND USES THEREOF | Academia Sinica (TW) | 2016-12-07 | — | — | EP | disclosed |
| US-20160347795-A1 | TEICOPLANIN ANALOGS AND USES THEREOF | ACADEMIA SINICA (TW) | 2016-12-01 | — | — | US | disclosed |
| WO-2015116537-A9 | TEICOPLANIN ANALOGS AND USES THEREOF | ACADEMIA SINICA (TW) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015116537-A1 | TEICOPLANIN ANALOGS AND USES THEREOF | ACADEMIA SINICA (TW) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316064-B2 | Teicoplanin analogs and uses thereof | NGLY1, VIP, NRDC | EP300 3259/4885NAA50 1570/4885AURKA 2573/4885 |
| US-20170327542-A9 | TEICOPLANIN ANALOGS AND USES THEREOF | NGLY1, VIP, NRDC | EP300 3318/4885NAA50 1599/4885AURKA 2643/4885 |
| US-20160347795-A1 | TEICOPLANIN ANALOGS AND USES THEREOF | NGLY1, VIP, NRDC | EP300 3318/4885NAA50 1599/4885AURKA 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.